NanoViricides (NNVC)
XASE:NNVC
Want to see NNVC full AI Analyst Report?
NNVC Stock Chart & Stats
$1.13
-$0.10(-6.54%)
At close: 4:00 PM EST
$1.13
-$0.10(-6.54%)
Day’s Range― - ―
52-Week Range$0.85 - $2.23
Previous CloseN/A
Volume409.80K
Average Volume (3M)143.34K
Market Cap
$40.26M
Enterprise Value-$3.21T
Total Cash (Recent Filing)$3.21T
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Nov 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding21,647,000
10 Day Avg. Volume199,739
30 Day Avg. Volume143,335
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.82
Price to Sales (P/S)0.00
P/FCF Ratio-2.48
Enterprise Value/Market Cap-79.81K
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit24.79M
Enterprise Value/Ebitda424.18K
Forecast
1Y Price Target
$6.00Price Target Upside430.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.35
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Platform & PipelineNanoViricides’ nanoviricide platform is a structural competitive asset: it mimics host-cell binding to disrupt viral particles, enabling multiple drug formats (e.g., NV-387 and remdesivir-encapsulated). This platform breadth supports durable pipeline expansion, licensing or partner strategies across viral indications.
Low Financial LeverageNear-zero debt materially reduces fixed obligations and bankruptcy risk, giving management strategic flexibility. For a pre-commercial biotech, low leverage lowers near-term financial stress and improves optionality to pursue trials, partnerships, or opportunistic M&A without debt-servicing constraints.
Access To Capital MarketsThe recent registered direct offering demonstrates the company can secure institutional financing and use shelf registration mechanics. Proceeds are earmarked for R&D/clinical needs, showing an operational ability to fund programs and extend runway—an important structural capability for continuing development.
Bears Say
No Revenue / Pre-commercial ProfileNNVC remains pre-commercial with zero reported revenue and persistent net losses. Without commercialized products, the firm lacks internally generated cash flow, making long-term sustainability dependent on successful trials, milestone payments, or continued external financing rather than operating earnings.
Consistent Cash BurnSteady annual free-cash-flow burn creates an enduring need for capital infusions. Predictable but material cash consumption constrains strategic choices, elevates dilution risk from follow-on financings, and forces prioritization of programs, which can delay broader pipeline development absent non-dilutive funding.
Unusual TTM Loss & Balance-sheet AnomalyThe unusually large trailing-twelve-month loss and anomalous balance-sheet items impair trend comparability and forecasting. Such anomalies can signify one-time charges or reporting changes that obscure true operating performance, increasing investor and creditor uncertainty when assessing long-term viability.
NanoViricides News
NNVC FAQ
What was NanoViricides’s price range in the past 12 months?
NanoViricides lowest stock price was $0.85 and its highest was $2.23 in the past 12 months.
What is NanoViricides’s market cap?
NanoViricides’s market cap is $40.26M.
When is NanoViricides’s upcoming earnings report date?
NanoViricides’s upcoming earnings report date is Nov 23, 2026 which is in 176 days.
How were NanoViricides’s earnings last quarter?
NanoViricides released its earnings results on Nov 24, 2025. The company reported -$0.135 earnings per share for the quarter, beating the consensus estimate of -$0.18 by $0.045.
Is NanoViricides overvalued?
According to Wall Street analysts NanoViricides’s price is currently Undervalued.
Does NanoViricides pay dividends?
NanoViricides does not currently pay dividends.
What is NanoViricides’s EPS estimate?
NanoViricides’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NanoViricides have?
NanoViricides has 21,647,000 shares outstanding.
What happened to NanoViricides’s price movement after its last earnings report?
NanoViricides reported an EPS of -$0.135 in its last earnings report, beating expectations of -$0.18. Following the earnings report the stock price went down -2.362%.
Which hedge fund is a major shareholder of NanoViricides?
Currently, no hedge funds are holding shares in NNVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NanoViricides Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (430.97% Upside)
$6.00 (430.97% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.3%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.67%
12-Months-Change
Fundamentals
Return on Equity
>-0.01%
Trailing 12-Months
Asset Growth
1.86%
Trailing 12-Months
Company Description
NanoViricides
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
NNVC Stock 12 Month Forecast
Average Price Target
$6.00
▲(430.97% Upside)
Technical Analysis
Ownership Overview
―
Insiders
3.18% Mutual Funds
0.98% Other Institutional Investors
93.49% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---